Clopidogrel Tablet, Film Coated
Product Images NDC 55154-2149

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 55154-2149). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

75mg Bag Label (C03a895c 2d74 4d7f 891f B752ce409b68 00)

Text panel for Clopidogrel Tablets USP 75 mg, containing 10 film-coated tablets. The panel provides dosage information, storage conditions, warnings about child resistance and institutional use, pharmacy dispensing instructions, and distribution details including manufacturers Apotex Corp and Cardinal Health.*

FDA Label Image

Figure 1: Exposure To Clopidogrel Active Metabolite Following Multiple Doses Of Clopidogrel 75 mg Alone Or With Proton Pump Inhibitors (ppis) (Figure1)

A horizontal error bar chart illustrating the effect of co-administered proton pump inhibitors (PPIs) on the active metabolite AUC of Clopidogrel. The chart compares Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg, with mean values and 90% confidence intervals showing change relative to Clopidogrel administered alone.*

FDA Label Image

Figure 2: Cardiovascular Death, Myocardial Infarction, And Stroke In The Cure Study (Figure2)

A line graph showing cumulative event rates (%) of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. It compares outcomes between placebo plus aspirin and clopidogrel plus aspirin, with the clopidogrel group demonstrating a lower event rate. A p-value of 0.00009 indicates statistical significance. The graph notes that other standard therapies were used as appropriate.*

FDA Label Image

Figure 3: Hazard Ratio For Patient Baseline Charecteristics And On-study Concomitant Medications/interventions For The Cure Study (Figure3a)

A forest plot comparing hazard ratios between Clopidogrel and placebo across various subgroups. Subgroups include age, gender, race, elevated cardiac enzymes, diabetes status, previous myocardial infarction, and previous stroke. The plot shows hazard ratios with 95% confidence intervals, indicating relative favorability between Clopidogrel and placebo for each subgroup, including an overall comparison.*

FDA Label Image

Figure 3: Hazard Ratio For Patient Baseline Characteristics And On-study Concomitant Medications/interventions For The Cure Study (continued) (Figure3b)

A forest plot comparing subgroups in a clinical study of Clopidogrel versus placebo. The chart shows hazard ratios with 95% confidence intervals for various subgroups defined by heparin/LMWH use, aspirin dosage, GP IIb/IIIa antagonist use, beta-blocker use, and ACE inhibitor use. The plot includes sample sizes, event counts, and percentages for each treatment group, with a horizontal axis indicating hazard ratios favoring Clopidogrel or placebo.*

FDA Label Image

Figure 4: Cumulative Event Rates For Death In The Commit Study* (Figure4)

A Kaplan-Meier survival curve comparing percent mortality before first discharge over 28 days between Clopidogrel and placebo groups. The graph shows deaths for placebo (1845 deaths, 8.1%) and Clopidogrel (1726 deaths, 7.5%), indicating a 7% proportional risk reduction with Clopidogrel. The x-axis represents days since randomization, and the y-axis shows percent dead before discharge.*

FDA Label Image

Figure 5: Cumulative Event Rates For The Combined Endpoint Re-infarction, Stroke Or Death In The Commit Study* (Figure5)

A line graph comparing the percentage of patients experiencing death, reinfarction, or stroke before first discharge over 28 days by treatment group: Clopidogrel versus Placebo. The x-axis shows days since randomization, and the y-axis shows percent of patients with events. The graph indicates a lower event rate for Clopidogrel (9.2%) than Placebo (10.1%), noting a 9% proportional risk reduction (p=0.002). A footnote states all patients also received aspirin.*

FDA Label Image

Figure 6: Effects Of Adding Clopidogrel To Aspirin On The Combined Primary Endpoint Across Baseline And Concomitant Medication Subgroups For The Commit Study (Figure6)

A forest plot chart displaying odds ratios with 99% confidence intervals for various subgroups of a clinical analysis, including gender, age, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent administration. Each subgroup compares Clopidogrel versus placebo, showing percentages and odds ratios with a vertical line at 1.0 indicating no effect.*

FDA Label Image

Figure 7: Fatal Or Nonfatal Vascular Events In The Caprie Study (Figure7)

A line chart titled 'Fatal or Non-Fatal Vascular Events' showing cumulative event rate (%) on the y-axis and months of follow-up on the x-axis. It compares two treatments, Aspirin and Clopidogrel, over 36 months with a p-value of 0.045 indicated.*

FDA Label Image

Figure 8: Hazard Ratio And 95% Ci By Baseline Subgroups In The Caprie Study (Figure8)

A forest plot comparing the hazard ratios of Clopidogrel versus Aspirin across different qualifying conditions including Stroke, MI, PAD, and Overall. The plot displays event counts and percentages for Clopidogrel and Aspirin groups and shows markers indicating whether outcomes favor Clopidogrel or Aspirin, with a hazard ratio scale ranging approximately from 0.6 to 1.3.*

FDA Label Image

Structural Formula (Structure)

Chemical structure of Clopidogrel Bisulfate showing the molecular arrangement including a thiophene ring, a chlorophenyl group, and a carboxylate ester functional group with sulfate indicated as H2SO4.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.